Literature DB >> 6227669

Suppression of the responsiveness of lymphocytes from cancer patients triggered by co-culture with autologous tumor-derived cells.

M Akiyama, M A Bean, K Sadamoto, Y Takahashi, V Brankovan.   

Abstract

The question as to whether or not cancer patients have "tumor antigen"-induced suppressor T cells is of considerable interest and importance. As an approach to that question, the effect of addition of autologous irradiated tumor-derived cells (TDC) on the mixed lymphocyte response (MLR) of patients' lymphocytes (Ly) and of healthy donor Ly was tested. The rationale for these experiments was based on the fact that circulating antigen-responsive blood lymphocytes can be reactivated in vitro by exposure to the appropriate antigen. Thus, if there are circulating tumor "antigen"-reactive suppressor Ly, exposure to TDC as a source of the antigen should reactivate those cells. Reactivation of suppressor cells might result in diminished responsiveness to other stimuli such as alloantigens in the mixed leukocyte culture. We found that the addition of TDC to Ly cultures produced four distinct patterns of reaction. In 26 of the 74 different patient-tumor assays, the addition of autologous TDC to the patient cultures inhibited MLR, but the addition of the same TDC to cultures of Ly from healthy donors had no effect or increased their responsiveness (Specific Suppression). In 21 cases, the addition of autologous TDC to the patient cultures suppressed the MLR and the addition of the same TDC to control cultures suppressed the response of some but not all the healthy donors (Selective Suppression). In four cases, the addition of TDC to the cultures suppressed the MLR of the patients and all of the control donors (Nonspecific Suppression). In 23 cases, the addition of autologous TDC resulted in no suppression of the patient MLR or of any of the simultaneously tested normal donors (No Suppression). When TDC of patients with noninvasive bladder cancer were added to their own Ly cultures, only four of 11 produced specific or selective suppression compared to 11 of 12 when TDC came from patients with superficially invasive cancer. These data provide indirect evidence to support the hypothesis that human tumors induce circulating suppressor cells that may be reactivated in vitro by co-culture with TDC.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227669

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.

Authors:  D Taramelli; A Mazzocchi; C Clemente; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma.

Authors:  M Nelson; D S Nelson; V K Kuchroo; P B Spradbrow; P A Jennings
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Surface phenotypes of human peripheral blood mononuclear cells from patients with gastrointestinal carcinoma.

Authors:  G Boltz; E Penner; C Holzinger; S Bakos; A Fellinger; M Walgram; C Wiltschke; H Rumpold; K Langer; A Gangl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.

Authors:  T L Knisely; J Y Niederkorn
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

Authors:  W R Klein; P A Steerenberg; F Poelma; E vd Wiel; V P Rutten; W Misdorp; W H de Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 7.  Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

Authors:  G Parmiani; G Fossati; D Taramelli; A Anichini; A Balsari; C Gambacorti-Passerini; G Sciorelli; N Cascinelli
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Authors:  M Lotem; T Peretz; O Drize; Z Gimmon; D Ad El; R Weitzen; H Goldberg; I Ben David; D Prus; T Hamburger; E Shiloni
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.